| Today's Big NewsJun 13, 2023 |
| By Angus Liu Biogen has taken a step to “significantly refresh” its board of directors, departing chair Stelios Papadopoulos, Ph.D., said. But the reported romantic relationship between a new nominee and a departing member raises questions about one appointment. |
|
|
|
By Phil Taylor Inspire Medical Systems has won an expanded label from the FDA for its eponymous medical device for obstructive sleep apnea (OSA) that should expand the number of people it can be used to treat. |
By Max Bayer Encoded Therapeutics is laying off almost 10% of its staff, nearly three years after raising a $135 million series D backed by GV, formerly Google Ventures. The company's lead asset is a gene therapy aimed at treating Dravet syndrome. |
By Eric Sagonowsky After Ipsen made a splash at this year's J.P. Morgan Healthcare Conference by scooping up liver disease specialist Albireo, the centerpiece of the buyout, Bylvay, has won a coveted label expansion. |
|
Wednesday, June 28, 2023 11:00am ET / 8:00am PT Join us for this this insightful webinar to learn how antibody profiling has been used to successfully identify novel diagnostic, prognostic, therapeutic, and predictive biomarkers in melanoma, prostate cancer, breast cancer, ovarian cancer, and rare cancers, yielding promising results.
|
|
By Nick Paul Taylor Turnstone Biologics is about to show whether public investors have regained their appetite for high-risk, high-reward programs. Having lost deals with AbbVie and Takeda, and shrunk its head count, the biotech has filed for an IPO to fund early-phase development of tumor-infiltrating lymphocytes (TILs). |
By Kevin Dunleavy Astellas’ new CEO Naoki Okamura didn’t waste any time in carrying out the company’s new mantra to be “aggressive” in its attempts to achieve growth. Less than a month into his tenure, Astellas made its largest acquisition in company history, buying Iveric Bio for $5.9 billion. |
By James Waldron The war of words between Erytech and an activist investor trying to stall the long-planned merger with Pherecydes has reignited this week, with both sides firing off stinging press releases. |
By Phil Taylor Merit Medical Systems has spent $132.5 million in the last few days to ramp up its presence in the hemodialysis device market, adding a range of catheter and sealant products it reckons will add around $33 million a year to its top line. |
By Ben Adams Most older adults aren’t aware of RSV vaccinations, but most would talk to and accept recommendations about these shots from their doctors. |
By Nick Paul Taylor Alladapt Immunotherapeutics has delivered early clinical evidence that it can desensitize multiple food allergies with a single oral immunotherapy. The phase 1/2 clinical trial reported dose-dependent changes in recipients of the multi-allergen candidate, encouraging Alladapt to plot a late-stage program. |
Fierce podcastsDon't miss an episode |
| This week on "The Top Line," we discuss the the top news from this year's annual ASCO meeting, plus contesting the Inflation Reduction Act, an ADHD video game, and the rest of the week's headlines. |
|
|---|
|
|
|
Monday, Jun 26, 2023 | 11:00 am ET Join us for a webinar on “The RESTORE Trial: First-Ever Lab-Grown RBCs” where Dr. Ashley Toye will talk about the first-ever clinical trial conducted for the transfusion of lab-grown red blood cells. Register now. |
|
| WhitepaperAutoantibody screening is promising for early cancer detection with the potential to improve the whole treatment decision tree, providing a less invasive, powerful approach. Sponsored by: Sengenics |
| WhitepaperExplore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment. Sponsored by: Catalent Clinical Supply |
| WhitepaperDiscover key considerations that every trial sponsor should know when navigating the complex clinical supply distribution landscape across Asia-Pacific. Sponsored by: Catalent |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| eBookSee how clinical trial sponsors can build stronger strategies to address challenges across the patient enrollment funnel, starting with four necessary steps. Sponsored by: OneStudyTeam |
| WhitepaperThis paper outlines various market archetypes and key considerations leaders must address when prioritizing new potential markets for gene therapies. Sponsored by: Blue Matter, strategic consultants in the life sciences |
| ResearchWhat role do the Library and Legal teams play in the drug development pipeline at Lilly? An import one – find out how. Sponsored by: CCC |
| |
|
